World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
48
Citations
15837
World Ranking
4384
National Ranking
7

Sorachai Nitayaphan publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Sorachai Nitayaphan sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 184 publications — 28th percentile

28% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Sorachai Nitayaphan D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Sorachai Nitayaphan sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 48 D-Index — 11th percentile

11% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

Sorachai Nitayaphan is affiliated with the Armed Forces Research Institute of Medical Science in Thailand. The scientist's research spans key fields such as Immunology and Microbiology, with focused subfields including Virology, Immunology, Infectious Diseases, Epidemiology, and Radiology, Nuclear Medicine and Imaging.

The main topics addressed in their work include HIV Research and Treatment, Immune Cell Function and Interaction, HIV/AIDS Research and Interventions, T-cell and B-cell Immunology, Monoclonal and Polyclonal Antibodies Research, HIV/AIDS drug development and treatment, and Virology and Viral Diseases.

Recent publications authored or co-authored by Sorachai Nitayaphan include:

  • "Global variability of the human IgG glycome," 2020, Aging
  • "Dynamic MAIT cell response with progressively enhanced innateness during acute HIV-1 infection," 2020, Nature Communications
  • "Late boosting of the RV144 regimen with AIDSVAX B/E and ALVAC-HIV in HIV-uninfected Thai volunteers: a double-blind, randomised controlled trial," 2020, The Lancet HIV
  • "Molecular dating and viral load growth rates suggested that the eclipse phase lasted about a week in HIV-1 infected adults in East Africa and Thailand," 2020, PLoS Pathogens
  • "RV144 HIV-1 vaccination impacts post-infection antibody responses," 2020, PLoS Pathogens

Frequent publication venues for Sorachai Nitayaphan include PLoS Pathogens, JCI Insight, Frontiers in Immunology, UNC Libraries, and PLoS ONE.

They have collaborated regularly with several co-authors, notably Merlin L. Robb, Sandhya Vasan, Nelson L. Michael, Punnee Pitisuttithum, and Robert J. O'Connell.

Best Publications

  • Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand

    Supachai Rerks-Ngarm;Punnee Pitisuttithum;Sorachai Nitayaphan;Jaranit Kaewkungwal

  • Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy Trial

    Barton F. Haynes;Peter B. Gilbert;M. Juliana McElrath;Susan Zolla-Pazner

  • Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2

    Morgane Rolland;Paul T. Edlefsen;Brendan B. Larsen;Sodsai Tovanabutra

  • Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination

    Nicole L. Yates;Nicole L. Yates;Hua Xin Liao;Hua Xin Liao;Youyi Fong;Allan DeCamp

  • Antibody-Dependent Cellular Cytotoxicity-Mediating Antibodies from an HIV-1 Vaccine Efficacy Trial Target Multiple Epitopes and Preferentially Use the VH1 Gene Family

    Mattia Bonsignori;Justin Pollara;M. Anthony Moody;Michael D. Alpert

  • Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG

    Georgia D. Tomaras;Guido Ferrari;Xiaoying Shen;S. Munir Alam

  • Polyfunctional Fc-Effector Profiles Mediated by IgG Subclass Selection Distinguish RV144 and VAX003 Vaccines

    Amy W. Chung;Musie Ghebremichael;Hannah Robinson;Eric Brown

  • Vaccine Induction of Antibodies against a Structurally Heterogeneous Site of Immune Pressure within HIV-1 Envelope Protein Variable Regions 1 and 2

    Hua Xin Liao;Mattia Bonsignori;S. Munir Alam;Jason S. McLellan

  • Magnitude and Breadth of the Neutralizing Antibody Response in the RV144 and Vax003 HIV-1 Vaccine Efficacy Trials

    David C. Montefiori;Chitraporn Karnasuta;Ying Huang;Hasan Ahmed

  • Prospective Study of Acute HIV-1 Infection in Adults in East Africa and Thailand

    Merlin L Robb;Leigh A Eller;Hannah Kibuuka;Kathleen Rono

  • Vaccine-induced IgG antibodies to V1V2 regions of multiple HIV-1 subtypes correlate with decreased risk of HIV-1 infection

    Susan Zolla-Pazner;Allan DeCamp;Peter B. Gilbert;Constance Williams

  • COMPASS identifies T-cell subsets correlated with clinical outcomes

    Lin Lin;Greg Finak;Kevin Ushey;Chetan Seshadri

  • Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144.

    Merlin L Robb;Supachai Rerks-Ngarm;Sorachai Nitayaphan;Punnee Pitisuttithum

  • Plasma IgG to Linear Epitopes in the V2 and V3 Regions of HIV-1 gp120 Correlate with a Reduced Risk of Infection in the RV144 Vaccine Efficacy Trial

    Raphael Gottardo;Robert T. Bailer;Bette T. Korber;S. Gnanakaran

  • The Thai Phase III HIV Type 1 Vaccine Trial (RV144) Regimen Induces Antibodies That Target Conserved Regions Within the V2 Loop of gp120

    Nicos Karasavvas;Erik Billings;Mangala Rao;Constance Williams

  • HIV-1 vaccine-induced C1 and V2 Env-specific antibodies synergize for increased antiviral activities.

    Justin Pollara;Mattia Bonsignori;M. Anthony Moody;Pinghuang Liu

  • The Thai Phase III Trial (RV144) Vaccine Regimen Induces T Cell Responses That Preferentially Target Epitopes within the V2 Region of HIV-1 Envelope

    Mark S. de Souza;Mark S. de Souza;Silvia Ratto-Kim;Weerawan Chuenarom;Alexandra Schuetz;Alexandra Schuetz

  • Safety and immunogenicity of an HIV subtype B and E prime-boost vaccine combination in HIV-negative Thai adults

    Sorachai Nitayaphan;Punnee Pitisuttithum;Chitraporn Karnasuta;Chirapa Eamsila

  • Analysis of V2 antibody responses induced in vaccinees in the ALVAC/AIDSVAX HIV-1 vaccine efficacy trial.

    Susan Zolla-Pazner;Susan Zolla-Pazner;Allan C. deCamp;Timothy Cardozo;Nicos Karasavvas

  • Dual Infection with Human Immunodeficiency Virus Type 1 of Distinct Envelope Subtypes in Humans

    Andrew W. Artenstein;Thomas C. VanCott;John R. Mascola;Jean K. Carr

  • CD8 and CD4 epitope predictions in RV144: no strong evidence of a T-cell driven sieve effect in HIV-1 breakthrough sequences from trial participants.

    Kalpana Dommaraju;Gustavo Kijak;Jonathan M. Carlson;Brendan B. Larsen

Frequent Co-Authors

Merlin L. Robb
Merlin L. Robb Walter Reed Army Institute of Research
Nelson L. Michael
Nelson L. Michael Walter Reed Army Institute of Research
Punnee Pitisuttithum
Punnee Pitisuttithum Mahidol University
Jerome H. Kim
Jerome H. Kim Walter Reed Army Institute of Research
Peter B. Gilbert
Peter B. Gilbert Fred Hutchinson Cancer Research Center
Georgia D. Tomaras
Georgia D. Tomaras Duke University
Morgane Rolland
Morgane Rolland Henry M. Jackson Foundation
David C. Montefiori
David C. Montefiori Duke University
Barton F. Haynes
Barton F. Haynes Duke University
Deborah L. Birx
Deborah L. Birx Centers for Disease Control and Prevention

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in advancing their knowledge in Immunology, several related healthcare degrees offer complementary career opportunities. Many students start with foundational nursing programs before specializing further. For example, exploring the fastest and easiest lpn programs can provide a quick pathway into the nursing field, allowing you to gain practical experience and build a strong healthcare foundation.

Once you've acquired nursing credentials, pursuing specialized roles such as a Nurse Practitioner can broaden career possibilities. The easy nurse practitioner programs to get into can offer a smoother transition into advanced practice roles, combining clinical skills with immunological knowledge for patient care and research.

For those particularly interested in mental health and its connection to immune-related disorders, investigating the best online pmhnp programs ensures quality education that balances theory with hands-on clinical placements. This can be invaluable for providing comprehensive psychiatric care.

Additionally, staying cost-conscious is important when selecting programs. The cheapest psychiatric nurse practitioner programs provide affordable options without compromising quality, making advanced degrees more accessible for many learners.

By exploring these pathways, students and professionals can tailor their careers to intersect effectively with Immunology, enhancing both patient outcomes and scientific understanding.

Best Scientists Citing Sorachai Nitayaphan

Trending Scientists

Recently Published Articles